Kutki: The Liver Herb Western Medicine Is Finally Studying

Dr. Meera Iyer — Sat, 21 Feb 2026 16:45:53 +0000

Kutki, the Hindi name commonly used for Ayurvedic Kaṭukā (Picrorhiza kurroa Royle ex Benth.), is a bitter Himalayan perennial whose dried rhizome with attached root is an official Ayurvedic drug. Modern pharmacological interest centres on iridoid glycosides and on picroliv, a standardized fraction prepared from the underground parts. Its traditional importance is well established, but its modern clinical evidence is much smaller than the promotional language surrounding many “liver detox” products suggests.

What Makes Kutki Different From Other “Liver Herbs”

Kutki should not be treated as an Ayurvedic version of milk thistle. The two plants contain different chemical groups, have different traditions of use and have not been shown to be interchangeable. Kutki contains picrosides, kutkoside and other constituents such as apocynin and androsin. Picroliv is generally described as a fraction rich in picroside I and kutkoside; it is not identical to crude Kutki powder or to every commercial “standardized extract.”

Bile-related effects: Picroliv increased bile flow and bile constituents and opposed experimentally induced cholestasis in rats and other laboratory animals. This was a preclinical finding, not proof that Kutki treats human biliary disease or supports a defined “Phase II detoxification” pathway.
Antioxidant activity: Picroliv, picroside I and kutkoside scavenged superoxide anions in laboratory experiments. Animal models also report protection against several chemically induced forms of liver injury.
Metabolic liver models: Standardized extracts have been investigated in high-fat-diet models, and a 2025 picroside-rich fraction reduced steatohepatitis-related changes in zebrafish and mice. These results establish experimental activity, not clinical effectiveness.
Multiple preparations: Whole rhizome powder, aqueous or alcoholic extracts and picroliv differ in composition and dose. Findings from one preparation cannot automatically be assigned to another.

What the Evidence Actually Shows

The best-known published human trial is an older, small study in acute viral hepatitis. Much of the mechanistic literature comes from cell or animal experiments. The evidence supports continued investigation, but not the replacement of antiviral treatment, metabolic care or specialist management of chronic liver disease.

Study	Design	Finding	Interpretation
Vaidya et al., 1996	Randomized double-blind placebo-controlled trial; 33 HBsAg-negative patients with acute viral hepatitis	Root powder 375 mg three times daily for two weeks was associated with lower bilirubin and transaminase values and a shorter time to bilirubin reduction than placebo	Preliminary human evidence from a small, older study
Shukla et al., 1991	Animal pharmacology	Picroliv produced dose-dependent choleretic and anticholestatic effects	Does not establish a human treatment dose
Chander et al., 1992	Laboratory antioxidant study	Picroliv, picroside I and kutkoside scavenged superoxide anions	Mechanistic support only
Shetty et al., 2010	High-fat-diet rat model	Standardized extracts were assessed for reversal of fatty-liver changes	Experimental NAFLD study, not a clinical trial
Katoch et al., 2025	Zebrafish and mouse models of steatohepatitis	A picroside-rich fraction reduced lipid accumulation, inflammation and fibrosis-related changes	Recent preclinical evidence

Human trials have not established Kutki as a stand-alone treatment for chronic hepatitis, fibrosis, cirrhosis, drug-induced liver injury or metabolic fatty liver disease.

Kutki in the Ayurvedic Pharmacopoeia

The Ayurvedic Pharmacopoeia of India gives Kutki katu and tikta rasa (pungent and bitter tastes), laghu guṇa (light quality), śīta vīrya (cooling potency) and katu vipāka (pungent post-digestive effect). Its listed actions are hṛdya, pittahara, dīpanī, bhedinī and jvarahara. Listed therapeutic uses include śvāsa, dāha, jvara, kāmalā, kuṣṭha, viṣamajvara and arocaka.

The pharmacopoeial profile is not simply “bitter and cooling”: it also includes katu rasa alongside the śīta vīrya. The monograph identifies the dried rhizome with root as the drug and lists Ārogyavardhinī Guṭikā, Tiktaka Ghṛta, Sarvajvarahara Lauha and Mahātiktaka Ghṛta among important formulations. Classical terms such as kāmalā should be interpreted within Ayurvedic diagnosis; they are not automatic synonyms for every modern cause of jaundice or liver-enzyme elevation.

Whole Herb, Extract and Classical Formulation

Crude Kutki powder retains a broad plant matrix, whereas standardized fractions are manufactured to control selected markers. That distinction improves reproducibility in trials but also means that milligram doses are not interchangeable. A capsule labelled only “Kutki extract” is incomplete unless it states the botanical identity, plant part, extraction ratio or marker specification and manufacturer quality controls.

Ārogyavardhinī is a separate multi-ingredient herbo-mineral medicine, not simply a higher dose of Kutki. Traditional versions may contain processed mercury, sulfur, copper, iron and mica ingredients along with herbs. It should therefore be obtained from a properly licensed source and used only under qualified Ayurvedic supervision rather than self-prescribed from an unverified online formula.

Dosing: What Can Be Stated Reliably

The Ayurvedic Pharmacopoeia gives a dose of 1–3 g of the drug in powder form. Health Canada’s current adult monograph likewise specifies 1–3 g daily of dried root or rhizome for traditional bitter-tonic or liver-protectant claims. These figures apply to dried, non-standardized material and do not create a universal dose for concentrated extracts.

Crude powder: 1–3 g daily is the pharmacopoeial range; individual selection of dose, vehicle and duration belongs to clinical practice.
Older hepatitis trial: 375 mg of root powder three times daily for two weeks was the studied regimen, not a general prescription for hepatitis.
Picroliv trial product: the registered Phase III protocol uses 100 mg twice daily for 24 weeks in addition to standard care. This investigational fraction is not equivalent to ordinary Kutki capsules.

Course length is individualized; an eight-to-twelve-week default is not part of the pharmacopoeial monograph. Persistent jaundice, dark urine, pale stools, abdominal swelling, vomiting, confusion or unexplained liver-test abnormalities require prompt medical assessment.

Safety Profile and Contraindications

Safety information for Kutki is less extensive than for established medicines. Its pharmacopoeial bhedinī action and recognized laxative use are clinically relevant: loose stools or a laxative effect can occur. Health Canada advises adults to separate Kutki from other medicines or health products by a few hours and lists pregnancy, breastfeeding, fever and undiagnosed gastrointestinal trouble among situations in which the product should not be used.

Pregnancy and breastfeeding: do not use Kutki.
Children: the Health Canada monograph provides adult dosing only; pediatric use requires professional assessment.
Liver or biliary disease: do not self-treat jaundice, hepatitis, gallbladder symptoms or abnormal liver tests. Preclinical choleretic activity does not establish safety in biliary obstruction.
Medicines: a prescriber or pharmacist should review concurrent medicines, particularly treatments with a narrow therapeutic range.

Kutki Compared With Milk Thistle

A comparison is useful only when it preserves the limits of both evidence bases. Milk thistle has been tested in more human liver-disease trials, but the US National Center for Complementary and Integrative Health describes the results as conflicting or too limited for firm conclusions. Kutki has a smaller human literature and a larger proportion of preclinical work.

Parameter	Kutki	Milk Thistle
Main studied constituents	Picrosides, kutkoside and the picroliv fraction	Silymarin flavonolignans, including silybin
Human liver evidence	Very limited; one small older acute-hepatitis trial is central	More trials, but findings remain inconsistent across liver conditions
Traditional identity	Official Ayurvedic drug with dīpanī, bhedinī and jvarahara actions	Botanical used in Western herbal traditions
Conservation	Globally Endangered and included in CITES Appendix II	Not subject to the same Kutki-specific trade concern

Sustainability and Authentic Sourcing

The 2021 IUCN assessment lists Picrorhiza kurroa as Endangered and identifies overexploitation, habitat loss and destructive uprooting among the pressures on wild populations. The species is also controlled under CITES Appendix II. Ethical purchasing therefore requires more than a generic “Himalayan” label: suppliers should provide correct botanical identity, legal traceability and cultivated or otherwise demonstrably sustainable material.

Current Clinical Development

ClinicalTrials.gov lists NCT07452744, a Phase III multicentre randomized double-blind placebo-controlled study of picroliv in 170 adults with uncomplicated NAFLD. The protocol uses picroliv 100 mg twice daily plus standard care for 24 weeks, with longer follow-up. Until results are posted and independently assessed, the trial is evidence of active development rather than proof of benefit.

Kutki is an authentic Ayurvedic drug with a defined pharmacopoeial profile, substantial experimental pharmacology and limited human evidence. Responsible use means matching the preparation to the tradition or trial being cited, avoiding exaggerated liver-detox claims, choosing sustainable material and keeping medical diagnosis and standard treatment central.

Disclaimer: This article is for educational purposes and does not constitute medical advice. Consult a qualified Ayurvedic practitioner and an appropriate healthcare provider before using Kutki, especially during treatment for liver, gallbladder or gastrointestinal disease or when taking prescription medicines. Do not use Kutki or an Ayurvedic formulation as a replacement for prescribed care.

picrosides – Ayurved Healing